

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6561421

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GERARD HILINSKI	12/20/2018
SO YOUN SHIM	11/30/2018
MATTHEW REISER PATTON	01/03/2019
JOHN HANNEY MCGEE	11/30/2018
PAULA ORTET	12/19/2018
GREGORY L. VERDINE	11/30/2018
RECEIVING PARTY DATA	
Name:	FOG PHARMACEUTICALS, INC.
Street Address:	100 ACORN PARK DRIVE
Internal Address:	6TH FLOOR
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02140
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16645407
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-248-5000
Email:	PatentDocket@choate.com
Correspondent Name:	CHOATE HALL & STEWART LLP-PATENT DOCKET
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2012675-0124
NAME OF SUBMITTER:	XIAODONG LI
SIGNATURE:	/Xiaodong Li/
DATE SIGNED:	02/19/2021

Total Attachments: 11

source=Assignment#page1.tif
source=Assignment#page2.tif
source=Assignment#page3.tif
source=Assignment#page4.tif
source=Assignment#page5.tif
source=Assignment#page6.tif
source=Assignment#page7.tif
source=Assignment#page8.tif
source=Assignment#page9.tif
source=Assignment#page10.tif
source=Assignment#page11.tif

COMBINED JOINT ASSIGNMENT & DECLARATION**A. ASSIGNMENT**

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Gerard Hilinski	Somerville, Massachusetts
2. So Youn Shim	Watertown, Massachusetts
3. Matthew Reiser Patton	Somerville, Massachusetts
4. John Hanney McGee	Somerville, Massachusetts
5. Paula Ortet	Malden, Massachusetts
6. Gregory L. Verdine	Boston, Massachusetts

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

**AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS
THEREOF; and**

☐ prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application No. _____
filed in the United States Patent and Trademark Office on _____; and

☒ identified by International Patent Application No. PCT/US18/50102
filed on September 7, 2018; and

☒ and is also aware of the following priority applications:

Application No.	Filed
62/555519	September 7, 2017

WHEREAS, **FOG PHARMACEUTICALS, INC.** (hereinafter "ASSIGNEE"), having a usual place of business at **100 Acorn Park Drive, 6th Floor, Cambridge, Massachusetts 02140**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold,

assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct application number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

B. DECLARATION (37 CFR 1.63)

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF;
and

☐ attached hereto or prepared for filing in the United States Patent and Trademark Office; or

☐ identified by United States Application No. _____
filed in the United States Patent and Trademark Office on _____; or


☒ identified by International Patent Application No. PCT/US18/50102
filed on September 7, 2018.

The above-identified application was made or authorized to be made by us.


We believe that we are each an original joint inventor of a claimed invention in the application.

We hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.


We have reviewed and understand the contents of the application, including the claims and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Signature: 
Gerard Hilinski

Date: 12/20/18

Witness Signature: 

Witness Name (printed): C. J. EVANS

Witness Signature: 

Witness Name (printed): Chad E. Bennett

Signature: So Youn Shim
So Youn Shim

Date: 2018.11.30

Witness Signature: [Signature]

Witness Name (printed): John McCabe

Witness Signature: [Signature]

Witness Name (printed): NEETI MITTAL

Signature: _____

Matthew Reiser Patton
Matthew Reiser Patton

Date: _____

1/3/2013

Witness Signature: _____

William R Patton

Witness Name (printed): _____

William R Patton

Witness Signature: _____

Elizabeth F Patton

Witness Name (printed): _____

Elizabeth F Patton

Signature: _____

John Hanney McGee

Date: _____

11/30/2018

Witness Signature: _____

Witness Name (printed): _____

Ivan Jewett

Witness Signature: _____

Witness Name (printed): _____

Ty Thomson

Signature:

Paula Ortet
Paula Ortet

Date: 12/19/18

Witness Signature:

L Baker

Witness Name (printed):


Lauren Ann Viarengo Baker

Witness Signature:


Kristina Stren

Witness Name (printed):

Dr. Kristina Stren

Signature: 
Gregory L. Verdine

Date: 11/30/18


Witness Signature: 

Witness Name (printed): John Melvøe

Witness Signature: 

Witness Name (printed): Jade Green

The undersigned (whose title is supplied below) is authorized to act on behalf of **FOG
PHARMACEUTICALS, INC.**

Signature:  Date: 11/30/18

Name (printed): Gregory L. Verdine

Title (printed): President and CEO